MedTrace Logo

The Effect of Melatonin and Vitamin C on COVID-19

NCT04530539 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2022-08-17

No results posted yet for this study

Summary

This is a double-blind placebo controlled trial that seeks to evaluate the impact of melatonin and vitamin C on symptoms and outcomes of patients with COVID-19.

Conditions

  • Covid19
  • SARS-CoV Infection

Interventions

DIETARY_SUPPLEMENT

Vitamin C

1000mg Vitamin C, at bedtime

DIETARY_SUPPLEMENT

melatonin

10mg melatonin, at bedtime

DIETARY_SUPPLEMENT

Placebo

Placebo at bedtime

OTHER

Symptom Survey

Daily symptom survey to be completed by patient electronically

Sponsors & Collaborators

  • Lancaster General Hospital

    lead OTHER

Principal Investigators

  • Corey Fogleman · Penn Medicine Lancaster General Health

  • Corey Fogleman, MD · Physician

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-05
Primary Completion
2022-08-11
Completion
2022-08-11

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04530539 on ClinicalTrials.gov